Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries
- 14 March 2011
- journal article
- research article
- Published by WHO Press in Bulletin of the World Health Organization
- Vol. 89 (6) , 412-421
- https://doi.org/10.2471/blt.10.084327
Abstract
Objective To investigate potential differences in the availability of medicines for chronic and acute conditions in low-and middle-income countries. Methods Data on the availability of 30 commonly-surveyed medicines - 15 for acute and 15 for chronic conditions - were obtained from facility-based surveys conducted in 40 developing countries. Results were aggregated by World Bank country income group and World Health Organization region. Findings The availability of medicines for both acute and chronic conditions was suboptimal across countries, particularly in the public sector. Generic medicines for chronic conditions were significantly less available than generic medicines for acute conditions in both the public sector (36.0% availability versus 53.5%; P=0.001) and the private sector (54.7% versus 66.2%; P=0.007). Antiasthmatics, antiepileptics and antidepressants, followed by antihypertensives, were the drivers of the observed differences. An inverse association was found between country income level and the availability gap between groups of medicines, particularly in the public sector. In low-and lower-middle income countries, drugs for acute conditions were 33.9% and 12.9% more available, respectively, in the public sector than medicines for chronic conditions. Differences in availability were smaller in the private sector than in the public sector in all country income groups. Conclusion Current disease patterns do not explain the significant gaps observed in the availability of medicines for chronic and acute conditions. Measures are needed to better respond to the epidemiological transition towards chronic conditions in developing countries alongside current efforts to scale up treatment for communicable diseases.This publication has 21 references indexed in Scilit:
- The Current Availability of Antiepileptic Drugs in Zambia: Implications for the ILAE/WHO “Out of the Shadows” CampaignThe American Journal of Tropical Medicine and Hygiene, 2010
- Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing WorldPLoS Medicine, 2010
- Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI dataBMC Cardiovascular Disorders, 2010
- Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysisPublished by Elsevier ,2008
- Evaluating Drug Prices, Availability, Affordability, and Price Components: Implications for Access to Drugs in MalaysiaPLoS Medicine, 2007
- AEDs Availability and Professional Practices in Delivery Outlets in a City Center in Southern VietnamEpilepsia, 2006
- Preventing chronic diseases: how many lives can we save?The Lancet, 2005
- A randomized controlled trial of an asthma clinical pathway for children in general practiceActa Paediatrica, 2005
- A randomized controlled trial of an asthma clinical pathway for children in general practiceActa Paediatrica, 2005
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998